Treatment Information

Back

Non-Hodgkin's Lymphoma treatment details. Chemotherapy, Hormone, Biologic therapy.

University Medical Center Groningen, University of Groningen, Groningen, Netherlands.

Survival: monthsCountry:Netherlands
Toxiciy Grade:5City/State/Province:Groningen
Treatments:Chemotherapy, Hormone, Biologic therapyHospital:University Medical Center Groningen, University of Groningen
Drugs:Journal:Link
Date:Jul 2011

Description:

Patients:
This phase 2 study involved 20 peripheral T-cell lymphoma patients. The median patient age was 50 years and 11 were male.

Treatment:
Patients were treated with the chemotherapy agents cyclophosphamide, doxorubicin, and vincristine, the hormone prednisone, and the biologic therapy agent alemtuzumab (an antibody against the CD52 protein that helps the immune system attack cancer cells).

Toxicities:
Treatment-related deaths due to infection were reported. Grade 4 allergic reactions and lung problems were also reported.

Results:
The median overall survival was 27 months.

Support:
This study was supported by Bayer Schering Pharma (makers of alemtuzumab) and Genzyme.

Correspondence: Dr. H. C. Kluin-Nelemans; email: [email protected]



Back